$SNGX What am I missing here? They just crushed the phase 3 trial with a 40% response compared to zero with placebo at 12 weeks, p<0.0001. They have an orphan drug designation for Cutaneous T-cell lymphoma AKA mycosis fungoides (common in AIDS patients). It is estimated there are 25K patients currently with this disease and 3K new per year. There have been no new onco drugs approved in the last 18 months without a 100K price tag or more. This is a miserable condition with disfigurement and itching. Assuming 20% penetration of 5K patients that means revenue of 500 million. Yet this company has a 50 million market cap. It seems seriously mispriced. What don't I know? It would seem an incredible bargain here.
  • 5
5 Likes